Login to Your Account

Carfilzomib Data Next Up for Onyx

Nexavar's 'MISSION' Continues Despite First-Line NSCLC Miss

By Jennifer Boggs

Tuesday, June 15, 2010
Multikinase inhibitor Nexavar's (sorafenib) failure in first-line non-small-cell lung cancer came as little surprise to investors of Onyx Pharmaceuticals Inc., who have their eyes trained on much-anticipated Phase IIb data for multiple myeloma drug carfilzomib, which, if positive, could be enough for an FDA filing late this year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription